Aprogen Biologics amends KRW 20 billion share sale to fund loan to Einspack

• Aprogen Biologics issued a correction to its Sept. 3 paid-in capital increase filing, reclassifying the funding purpose to “other funds.”
• The KRW 20 billion third-party allotment will fund strategic lending to EinsPack to support financial structure improvements.
• Shares to be issued remain 12,706,481 common shares at KRW 1,574 each, a 10% discount to a KRW 1,748 reference price.
• The allottee remains controlling shareholder Aprogen, subject to a one-year lock-up from the listing date.
• Payment date is Sept. 23, 2026; listing is scheduled for Oct. 13, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprogen Biologics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260923000418), on September 23, 2026, and is solely responsible for the information contained therein.